Filing Details

Accession Number:
0001209191-24-000879
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-04 18:28:49
Reporting Period:
2024-01-02
Accepted Time:
2024-01-04 18:28:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1761612 Bicycle Therapeutics Plc BCYC Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1788580 Nigel Crockett C/O Bicycle Therapeutics Plc
Blocks A &Amp; B, Portway Building
Cambridge X0 CB21 6GS
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2024-01-02 22,000 $0.00 51,359 No 4 A Direct
Ordinary Shares Disposition 2024-01-03 2,643 $17.50 48,716 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Employee Stock Option (right to buy) Acquisiton 2024-01-02 44,000 $0.00 44,000 $18.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
44,000 2034-01-02 No 4 A Direct
Footnotes
  1. Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
  2. Each RSU represents a contingent right to receive one ordinary share.
  3. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter.